LYPLA2 and melanoma: In summary, we did not observe biologically significant effects on cell growth and NRAS signaling following specific APT-1 and/or APT-2 inhibition in a panel of NRAS mutant melanoma cell lines using siRNA and the specific inhibitors ML348 and ML349.